Table 1.

Baseline disease history in JAK2p.V617F-positive patients by tertile

	Tertile 1 (−100% to ≤−24.66%) (n = 36)	Tertile 2 (>−24.66% to ≤−8%) (n = 36)	Tertile 3 (>−8%) (n = 35)
Maximum percent change in allele burden
Mean	−62.6	−15.3	−0.5
Median	−63.4	−14.8	−2.2
Baseline allele burden
Mean	70.9	73.5	75.3
Median	84.5	81.5	84.0
Duration of disease prior to treatment, months
Mean	36.8	52.5	44.8
Median	15.2	21.7	22.1
Tumor type, n (%)
Post-ET MF	4 (11.1)	5 (13.9)	10 (28.6)
Post-PV MF	17 (47.2)	17 (47.2)	15 (42.9)
PMF	15 (41.7)	14 (38.9)	10 (28.6)
IPSS risk level* at screening, n (%)
High risk	15 (41.7)	21 (60.0)	27 (77.1)
Intermediate-2 risk	21 (58.3)	14 (40.0)	8 (22.9)

IPSS, international prognostic scoring system; PMF, primary myelofibrosis.

^*Cervantes et al.¹⁸